197 related articles for article (PubMed ID: 30847025)
21. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
22. The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers.
Cavallari I; Ciccarese F; Sharova E; Urso L; Raimondi V; Silic-Benussi M; D'Agostino DM; Ciminale V
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34884985
[TBL] [Abstract][Full Text] [Related]
23. Correlation analysis of miR-200b, miR-200c, and miR-141 with liver metastases in colorectal cancer patients.
Zhu SH; He XC; Wang L
Eur Rev Med Pharmacol Sci; 2017 May; 21(10):2357-2363. PubMed ID: 28617555
[TBL] [Abstract][Full Text] [Related]
24. miR-200b restoration and DNA methyltransferase inhibitor block lung metastasis of mesenchymal-phenotype hepatocellular carcinoma.
Ding W; Dang H; You H; Steinway S; Takahashi Y; Wang HG; Liao J; Stiles B; Albert R; Rountree CB
Oncogenesis; 2012 Jun; 1(6):e15. PubMed ID: 23552699
[TBL] [Abstract][Full Text] [Related]
25. Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
Alunni-Fabbroni M; Majunke L; Trapp EK; Tzschaschel M; Mahner S; Fasching PA; Fehm T; Schneeweiss A; Beck T; Lorenz R; Friedl TWP; Janni W; Rack B;
BMC Cancer; 2018 Feb; 18(1):141. PubMed ID: 29409452
[TBL] [Abstract][Full Text] [Related]
26. Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer.
Imaoka H; Toiyama Y; Okigami M; Yasuda H; Saigusa S; Ohi M; Tanaka K; Inoue Y; Mohri Y; Kusunoki M
Gastric Cancer; 2016 Jul; 19(3):744-53. PubMed ID: 26233325
[TBL] [Abstract][Full Text] [Related]
27. miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases.
Liu J; Zhang X; Huang Y; Zhang Q; Zhou J; Zhang X; Wang X
Oncol Lett; 2019 Feb; 17(2):1453-1460. PubMed ID: 30675199
[TBL] [Abstract][Full Text] [Related]
28. Aberrant expression of microRNAs involved in epithelial-mesenchymal transition of HT-29 cell line.
Cai ZG; Zhang SM; Zhang H; Zhou YY; Wu HB; Xu XP
Cell Biol Int; 2013 Jul; 37(7):669-74. PubMed ID: 23483606
[TBL] [Abstract][Full Text] [Related]
29. Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-mir-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer.
Wee EJ; Peters K; Nair SS; Hulf T; Stein S; Wagner S; Bailey P; Lee SY; Qu WJ; Brewster B; French JD; Dobrovic A; Francis GD; Clark SJ; Brown MA
Oncogene; 2012 Sep; 31(38):4182-95. PubMed ID: 22231446
[TBL] [Abstract][Full Text] [Related]
30. Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker.
Erbes T; Hirschfeld M; Rücker G; Jaeger M; Boas J; Iborra S; Mayer S; Gitsch G; Stickeler E
BMC Cancer; 2015 Mar; 15():193. PubMed ID: 25886191
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer.
Yin J; Bai Z; Song J; Yang Y; Wang J; Han W; Zhang J; Meng H; Ma X; Yang Y; Wang T; Li W; Zhang Z
Chin J Cancer Res; 2014 Feb; 26(1):95-103. PubMed ID: 24653631
[TBL] [Abstract][Full Text] [Related]
32. Aberrant miRNAs expressed in HER-2 negative breast cancers patient.
Braicu C; Raduly L; Morar-Bolba G; Cojocneanu R; Jurj A; Pop LA; Pileczki V; Ciocan C; Moldovan A; Irimie A; Eniu A; Achimas-Cadariu P; Paradiso A; Berindan-Neagoe I
J Exp Clin Cancer Res; 2018 Oct; 37(1):257. PubMed ID: 30342533
[TBL] [Abstract][Full Text] [Related]
33. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-200c as a Prognostic Biomarker for Pancreatic Cancer.
Paik WH; Song BJ; Kim HW; Kim HR; Hwang JH
Korean J Gastroenterol; 2015 Oct; 66(4):215-20. PubMed ID: 26493507
[TBL] [Abstract][Full Text] [Related]
35. Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer.
Lv Z; Wei J; You W; Wang R; Shang J; Xiong Y; Yang H; Yang X; Fu Z
J Transl Med; 2017 Dec; 15(1):257. PubMed ID: 29258530
[TBL] [Abstract][Full Text] [Related]
36. Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients.
Markou A; Zavridou M; Sourvinou I; Yousef G; Kounelis S; Malamos N; Georgoulias V; Lianidou E
Clin Chem; 2016 Jul; 62(7):1002-11. PubMed ID: 27197674
[TBL] [Abstract][Full Text] [Related]
37. Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia.
Zhou JD; Zhang LC; Zhang TJ; Gu Y; Wu DH; Zhang W; Ma JC; Wen XM; Guo H; Lin J; Qian J
J Transl Med; 2018 May; 16(1):135. PubMed ID: 29784043
[TBL] [Abstract][Full Text] [Related]
38. Knockdown of circDENND4C inhibits glycolysis, migration and invasion by up-regulating miR-200b/c in breast cancer under hypoxia.
Ren S; Liu J; Feng Y; Li Z; He L; Li L; Cao X; Wang Z; Zhang Y
J Exp Clin Cancer Res; 2019 Sep; 38(1):388. PubMed ID: 31488193
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-200b Impacts Breast Cancer Cell Migration and Invasion by Regulating Ezrin-Radixin-Moesin.
Hong H; Yu H; Yuan J; Guo C; Cao H; Li W; Xiao C
Med Sci Monit; 2016 Jun; 22():1946-52. PubMed ID: 27276064
[TBL] [Abstract][Full Text] [Related]
40. The correlation of plasma microRNA-200 family expressions with risk and disease severity of lupus nephritis.
Zhang Y; Wang Y
Eur Rev Med Pharmacol Sci; 2018 May; 22(10):3118-3125. PubMed ID: 29863256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
